Skip to main content

Table 2 Comparison of median differences between Virgan use and no Virgan use

From: Efficacy and safety of topical ganciclovir in the management of cytomegalovirus (CMV)-related anterior uveitis

Virgan on vs Virgan off:

Median

IQR

p value

No. of episodes of uveitis recurrence per person year

−0.88

[−5.49–0.30]

0.029

Days-to-quiescence per episode of uveitis

−1.25

[−8.75–37.29]

0.610

Days-to-recurrence per episode of uveitis

−143.75

[−422.5–144.75]

0.285